Baird Assumes Danaher (DHR) at Outperform

April 7, 2021 8:02 AM EDT
Get Alerts DHR Hot Sheet
Price: $267.35 -0.41%

Rating Summary:
    27 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 5 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Baird analyst Catherine Schulte assumes coverage on Danaher (NYSE: DHR) with a Outperform rating and a price target of $249.00.

The analyst comments "We view DHR as a high-quality, core holding recommendation within the life science tools space, with attractive end-market exposures, high recurring revenue mix, and a strong capital deployment track record. We view the 2021 setup for DHR favorably, with overlapping COVID testing and vaccine/therapeutic tailwinds boosting what should be improving underlying end markets. Longer term, we think growth drivers like bioprocessing and point-of-care diagnostics could drive ~6% sustainable organic growth, with solid margin expansion and the potential for incremental M&A."

For an analyst ratings summary and ratings history on Danaher click here. For more ratings news on Danaher click here.

Shares of Danaher closed at $227.05 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird